Please login to the form below

Cytokinetics

This page shows the latest Cytokinetics news and features for those working in and with pharma, biotech and healthcare.

Amgen, Servier heart failure drug clears trial hurdle

Originally developed by Cytokinetics, omecamtiv is the first in a new class of drugs called cardiac myosin activators, that are designed to increase the duration of cardiac muscle contractility and improve ... Amgen recently started phase 1 trials of

Latest news

Amgen, Servier start second phase 3 trial of heart failure hope

Originally developed by Cytokinetics, omecamtiv is the first in a new class of drugs designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance in heart failure. ... Amgen, Servier and Cytokinetics are
Roche reshuffles its executive committee, again

Prior to joining Genetech Sabry was chief executive officer for start-up biotech and was founder and chief executive of biopharma Cytokinetics.
Amgen agrees to take Cytokinetics' heart failure drug into phase III

originator, Cytokinetics, which has been waiting for the big biotech to make a decision for several weeks. ... Cytokinetics said recently that meetings have been held with both the FDA and EMA to discuss the design of the outcomes study, which is due to
Biogen buys into Ionis' nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 
Roche buys rare disease firm Trophos in €470m deal

SMA therapy in development at Cytokinetics, while Biogen Idec and Isis Pharmaceuticals are also developing ISIS-SMNRx for the disease, a drug due to enter phase III soon.

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).
Deal Watch July 2016

Real Relationships. Astellas and Cytokinetics have announced another extension to their agreement involving the development of their skeletal muscle activators, tirasemtiv and CK-2127107. ... 181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and
Astellas: Ten years young

option, while in muscle disease Astellas is working with Californian clinical-stage biopharmaceutical company Cytokinetics, looking at mechanisms for improving muscle strength.
Heart failure therapy embarks on a new era

In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.
Deal Watch table for December 2014

Licence. 700. Cytokinetics / Astellas Pharma. CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Senior Medical Writer: Salary TBC

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Account Director, Medical Education: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Five key trends in precision and personalised healthcare: Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications: Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word: ...